David Balli Email & Phone Number

Pennsylvania, United States

Leverkusen, North Rhine-Westphalia, De

Lawrence Township, Nj, Us

* Built, mentored, and directly managed a team of 3 PhD-level computational biologists. Teamresponsibilities spanned early research and clinical development. Managed day-to-day analysisplanning as well as strategic objective setting with collaborators across the organization.* Responsible for overseeing analysis of multimodal biomarker and clinical datasets for late-stageoncology programs across NSCLC, SCLC, Mesothelioma, HNSCC, and early assets.* Leveraged clinical biomarker data to generate novel hypotheses and rationale for patient stratificationstrategies for multiple pre-clinical and early clinical programs.* Aided regulatory, clinical, and biostatisticians with exploratory biomarker analysis to supportsubmissions to regulatory agencies and public disclosures. Generated insights from internal andexternal data in real-time in support of strategic business development efforts. * Contributed to 6 scientific submitted abstracts and 3 publications in NEJM, Nature Medicine, JTO.

Lawrence Township, Nj, Us

* Responsible for data analysis supporting programs in NSCLC, Mesothelioma, SCLC, and HNSCC.* Successfully used novel machine learning algorithms on a multimodal dataset from a phase 3 clinical trial to identify translational opportunities for early clinical programs.* Managed a team of 2 PhD-level data scientists.* Contributed to 3 scientific submitted abstracts and 1 publication in NPJ Precision Oncology.

Lawrence Township, Nj, Us

* Led NSCLC and SCLC biomarker data analysis.* Identified biomarkers predictive of primary resistance to immunotherapy in first-line NSCLC patients.* Hired and managed a contract data scientist to support biomarker analysis across programs.* Contributed to 3 scientific abstracts and 1 publication in Annals of Oncology.

Lawrence Township, Nj, Us

* Performed biomarker analysis for SCLC and CRC indications.* Identified molecular subgroups within SCLC that differentiates response to immunotherapy.* Developed machine learning models for patient stratification within MSS-CRC.* Contributed to 1 scientific abstract and 2 publications in JCO Precision Oncology and JTO.

• Provided bioinformatics analysis and experimental design strategy for multiple pre-clinical and clinical programs under direct supervision of CSO.• Designed and developed novel tools for neoantigen identification and target selection for personalized and shared neoantigen vaccine programs beginning from pre-clinical development through FIH studies.• Applied machine learning methods to identify potential predictive biomarkers from clinical trial data that stratifies cancer patients likely to respond to an Advaxis Lm-based immunotherapy. • Contributed to the Parker Institutes’ Tumor Epitope SeLection Alliance (TESLA) consortium to improve the analytical approaches for identifying neoantigens.

Philadelphia, Pa, Us

• Investigated the immunogenomic and neoantigen landscape of pancreatic cancer using genetically engineered mouse models and human datasets (TCGA/ICGC, GEO/SRA, CCLE).• Contributed to an open-source, ensemble neoantigen identification project • Performed bioinformatics analysis for 6 peer-reviewed manuscripts in high-impact journals.• Performed single cell RNA sequencing analysis of circulating tumor cells for biomarker discovery.

B.A., Major: Biology, Minor: Biochemistry

Ph.D., Molecular And Developmental Biology